SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rick Strange who wrote (1120)3/27/2000 9:16:00 PM
From: arnie h  Read Replies (1) of 1386
 
<Doesn't the UCSD study of ICP by Marshall(?) et. al. make a compelling case that controlling ICP is a valid (maybe the only) predictor of outcome and morbidity?>

Rick: It'll be up to Dr. Marshall and others to convince the FDA of that point. Let's hope they can as it is sure worth a full effort.
On another subject, the short sales last month rose to about 800,000 shares from 400,000. Considering the large run up in price, this seems rather encouraging. Contrast that amount at the current $6-7 a share vs. the 1.3 million shares that were short when the stock was $1.25. Certainly seems the shorts are not inclined to be betting on the stock going down much vs.whatever was going on in the earlier period.
Cheers,
Arnie
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News